Head and neck cancer

29 trials 11 recruiting MedDRA PT
29 Registered trials
11 Recruiting
23 Unique sponsors
34 Unique IMPs
19 Commercial trials
Drug classes (ATC)
— ATC code not specified 16
L Oncology (ATC L) 10
N Neurology/Psychiatry (ATC N) 1
B Haematology (ATC B) 1
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (immune) 2 substances
Monoclonal antibody 2 substances
Antimetabolite 2 substances
Platinum compound 2 substances
Receptor fusion protein 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Supportive / diluent 1 substance
Monoclonal antibody (chimeric) 1 substance
Kinase inhibitor 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Macrolide / aminoglycoside 1 substance
Topoisomerase II inhibitor 1 substance
Alkylating agent 1 substance
Phase III: 5 Phase II: 10 Phase I/II: 2 Phase IV: 1 Phase I: 5 Phase I (Other): 1 Phase I (First in Human): 5

Filter these 29 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 29 trials

Phase III

5 trials
  • AstraZeneca AB Commercial
    MONALIZUMAB; SODIUM CHLORIDE
    2024-511813-39-00 1 country 2021 n=16
    Ended
  • Johnson & Johnson Enterprise Innovation Inc. Commercial
    CETUXIMAB; HAFNIUM OXIDE
    2024-520386-31-00 10 countries 2025 n=194
    Recruiting
  • OncoZenge AB Commercial
    BUPIVACAINE HYDROCHLORIDE MONOHYDRATE; LIDOCAINE HYDROCHLORIDE
    2025-524386-24-00 4 countries n=150
    Pending
  • Groupe Oncologie Radiotherapie Tete Cou Academic
    CETUXIMAB; XEVINAPANT
    2022-502584-38-00 1 country 2023 n=377
    Ended
  • Unicancer Academic
    IMP not specified
    2024-513707-14-00 1 country 2022 n=646
    Ended

Phase II

10 trials
  • Alx Oncology Inc. Commercial
    EVORPACEPT; PEMBROLIZUMAB
    2023-508340-22-00 3 countries 2021 n=50
    Ended
  • Alx Oncology Inc. Commercial
    EVORPACEPT; PEMBROLIZUMAB
    2023-508342-17-00 3 countries 2021 n=55
    Ended
  • Lisata Therapeutics Inc. Commercial
    LSTA1
    2023-503740-14-00 1 country n=20
    Ended
  • Seagen Inc. Commercial
    DISITAMAB VEDOTIN
    2023-504445-31-00 4 countries 2024 n=28
    Recruiting
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia Academic
    IMP not specified
    2024-518892-72-00 1 country n=30
    Pending
  • Cliniques Universitaires Saint-Luc Academic
    EZABENLIMAB
    2025-523575-36-00 1 country n=160
    Pending
  • Institut Gustave Roussy Academic
    INDOCYANINE GREEN
    2022-502737-26-00 2 countries 2020 n=65
    Recruiting
  • Institut Gustave Roussy Academic
    IPILIMUMAB; NIVOLUMAB
    2024-516810-39-00 1 country 2018 n=140
    Recruiting
  • Nanobiotix Academic
    CETUXIMAB
    2024-513082-39-00 3 countries 2022 n=60
    Ended
  • Unicancer Academic
    ZANIDATAMAB
    2025-522169-31-00 1 country 2025 n=105
    Recruiting

Phase I/II

2 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB; RELATLIMAB
    2023-508067-70-00 9 countries 2015 n=1,003
    Ended
  • Transgene Commercial
    AVELUMAB; TIPAPKINOGENE SOVACIVEC
    2024-515119-23-00 2 countries 2017 n=142
    Ended

Phase IV

1 trial
  • Turku University Hospital Academic
    BLEOMYCIN SULFATE PH. EUR.; CAPECITABINE; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; OXALIPLATIN
    2024-513437-21-00 1 country 2024 n=250
    Recruiting

Phase I

5 trials
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended
  • One-carbon Therapeutics AB Commercial
    IMP not specified
    2024-519639-40-00 2 countries 2025 n=33
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-506604-18-00 6 countries 2024 n=177
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-508469-34-00 2 countries 2020 n=238
    Recruiting
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended

Phase I (Other)

1 trial
  • USWM Ct LLC Commercial
    IMP not specified
    2024-512864-71-00 1 country 2020 n=32
    Ended

Phase I (First in Human)

5 trials
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Ipsen Pharma Commercial
    IPN01194
    2023-506228-10-00 2 countries 2024 n=36
    Ended
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
  • Taiho Oncology Inc. Commercial
    TOLINAPANT LACTATE
    2024-516679-33-00 2 countries 2017 n=16
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 3 Phase I, Phase II 3
Alx Oncology Inc. Commercial 2 Phase II 0
Salubris Biotherapeutics Inc. Commercial 2 Phase I (First in Human) 1
Institut Gustave Roussy Academic 2 Phase II 2
Unicancer Academic 2 Phase II, Phase III 1
Amgen Inc. Commercial 1 Phase I 0
One-carbon Therapeutics AB Commercial 1 Phase I 1
USWM Ct LLC Commercial 1 Phase I (Other) 0
Lisata Therapeutics Inc. Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase III 0
Johnson & Johnson Enterprise Innovation Inc. Commercial 1 Phase III 1
OncoZenge AB Commercial 1 Phase III 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Ipsen Pharma Commercial 1 Phase I (First in Human) 0
Taiho Oncology Inc. Commercial 1 Phase I (First in Human) 0
Bristol Myers Squibb International Corporation Commercial 1 Phase I/II 0
Transgene Commercial 1 Phase I/II 0
Incyte Corp. Academic 1 Phase I 0
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia Academic 1 Phase II 0
Cliniques Universitaires Saint-Luc Academic 1 Phase II 0
New trials by year
2020
3
2021
3
2022
4
2023
2
2024
4
2025
5
← All indication landscapes